Zoe Solsby

Jennifer Hollywood, PhD, University College Cork, Ireland, and Alan Davidson, PhD, University of Auckland, New Zealand Drs. Hollywood and Davidson are using rodent models to test a better variant of cysteamine and to find alternative therapies that target other pathways to improve the lives of patients with cystinosis. Since 2020, CRF has awarded $430,422 to

CRF is excited to announce the addition of two outstanding scientists to the CRF Scientific Review Board (SRB). These new members are experts in the field of cystinosis and have a deep commitment to the cystinosis community. With the expertise and dedication of our Scientific Review Board, we are changing the future of cystinosis. Please

CRF awarded Justine Bacchetta, MD, PhD, and Irma Machuca-Gayet, PhD, their first two-year cystinosis research grant in 2018 for the study of cysteamine toxicity on the bone that became known as the CYSTEABONE project. Additional grants have been awarded every two years since then to continue the research on the pathophysiology of bone disease in

Researcher Liang Feng, PhD, Associate Professor of Molecular and Cellular Physiology at Stanford University, received a grant award in 2022 for his research “Investigating the Molecular Basis of Protein Dynamics in Cystinosis”.  The goal of his study is to understand the molecular basis of protein dynamics that have important implications in cystinosis. Conformational transitions play

Researchers Francesco Emma, MD, Head Nephrology Unit, and Anna Taranta, PhD, Senior Research Associate, received grant funding in 2022 for their research on the “Impact of Diet Composition on Renal Function and Bone Disease of Ctns⁻/⁻ Mice.” The aim of their project is to define which dietary components are essential to develop a severe disease

 Xin Fan, PhD, Investigator and Morgan DiLeo, PhD, Mentor, University of Pittsburgh, Pennsylvania In the fall of 2022, CRF awarded this grant to Dr. DiLeo and her research fellow, Xin Fan, to investigate a sustained-release drug delivery mechanism to improve the treatment of ocular cystinosis, titled “Liposome cysteamine carriers for eye drop formulation with long-term